Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PSA markers in prostate cancer detection.

Matthew B Gretzer1, Alan W Partin

  • 1The James Buchanan Brady Urological Institute, Johns Hopkins Hospital, 600 N. Wolfe St./Marburg 1A, Baltimore, MD 21287, USA. gudoc@axs.net

The Urologic Clinics of North America
|December 19, 2003
PubMed
Summary

The prostate-specific antigen (PSA) revolution has improved prostate cancer detection. New PSA markers like free PSA and complexed PSA (cPSA) show promise for more specific diagnosis, potentially replacing traditional PSA screening.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.

BJU international·2024
Same author

Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.

European urology oncology·2023
Same author

ERG Status at the Margin Is Associated With Biochemical Recurrence After Radical Prostatectomy With Positive Surgical Margins.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2023
Same author

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection.

Cancers·2023
Same author

Successful replantation of self-amputated penis using microvascular repair resulting in restoration of voiding and erectile function.

Urology case reports·2023
Same author

Reply by Authors.

The Journal of urology·2022

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • The past two decades have seen significant advancements in prostate-specific antigen (PSA) utilization for prostate cancer detection and treatment.
  • Despite improvements, current PSA-based methods often lack specificity, leading to challenges in clinical interpretation.

Purpose of the Study:

  • To review the impact of evolving PSA markers on prostate cancer diagnosis.
  • To explore the potential of novel PSA forms and derivatives in enhancing diagnostic specificity.

Main Methods:

  • Review of literature on PSA, free PSA (%fPSA), and other PSA isoforms (proPSA, BPSA, iPSA).
  • Evaluation of emerging methods for detecting and measuring complexed PSA (cPSA).

Main Results:

Related Experiment Videos

  • %fPSA has shown improved discrimination between benign and malignant prostatic conditions.
  • Emerging markers like proPSA, BPSA, and iPSA offer potential for increased diagnostic specificity.
  • Complexed PSA (cPSA) detection methods have yielded promising results.

Conclusions:

  • New molecular forms of PSA represent a significant advancement in diagnostic markers.
  • Further research and clinical evaluation are needed for widespread adoption of these advanced PSA markers.
  • Complexed PSA (cPSA) may potentially replace PSA as a standard diagnostic test for prostate cancer screening.